PMLiVE |
GSK's severe asthma therapy Nucala gets EU nod
PMLiVE GlaxoSmithKline's first-in-class interleukin-5 (IL-5) inhibitor Nucala has been approved in the EU as a steroid-sparing therapy for patients with severe asthma. Nucala (mepolizumab) has been cleared by the European Commission as an add-on treatment for … |
View full post on asthma – Google News